Research
Hormonal
Tirzepatide (5-15 mg weekly) achieves mean weight loss of 15-21% in adults with BMI ≥27 kg/m², demonstrating superior efficacy compared to placebo and potentially other GLP-1 agonists.
Tirzepatide is a weekly injection available in doses up to 15mg. It can help you lose over 20% of your body weight if you have a BMI over 27. Side effects like nausea are common but often manageable. It is approved for obesity management in the US and UK.
StrongSupportsVERY_HIGH confidence
In individuals with BMI (cid:1)27 kg/m2 without T2D, mean (95% confidence interval) percentage change in weight with tirzepatide 5, 10 and 15 mg over 72 weeks was (cid:3)15.0% ((cid:3)14.2 to (cid:3)15.9), (cid:3)19.5% ((cid:3)20.4 to (cid:3)18.5) and (cid:3)20.9% ((cid:3)19.9 to (cid:3)21.8) compared to(cid:3)3.1 ((cid:3)4.3 to (cid:3)1.9) with placebo
Why this rating
Based on Phase 3 RCT (SURMOUNT 1) with N=2539.
Source
Obesity medications: A narrative review of current and emerging agents
Qi Q et al. · Osteoarthritis and Cartilage Open · 2024
DOI 10.1016/j.ocarto.2024.100472
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- New generation incretin analogues (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) produce sustained mean weight reductions of 15-20% in adults with BMI ≥27 kg/m², significantly outperforming older agents and lifestyle interventions alone.Strong
- Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →